JP2022115932A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022115932A5 JP2022115932A5 JP2022074779A JP2022074779A JP2022115932A5 JP 2022115932 A5 JP2022115932 A5 JP 2022115932A5 JP 2022074779 A JP2022074779 A JP 2022074779A JP 2022074779 A JP2022074779 A JP 2022074779A JP 2022115932 A5 JP2022115932 A5 JP 2022115932A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- vector
- expression
- optionally
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 13
- 210000002865 immune cell Anatomy 0.000 claims 12
- 108091027967 Small hairpin RNA Proteins 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 9
- 239000000427 antigen Substances 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 239000004055 small Interfering RNA Substances 0.000 claims 6
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 230000004068 intracellular signaling Effects 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 2
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 230000000139 costimulatory effect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 102000014450 RNA Polymerase III Human genes 0.000 claims 1
- 108010078067 RNA Polymerase III Proteins 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023200890A JP7763824B2 (ja) | 2018-01-12 | 2023-11-28 | 二重ｓｈＲＮＡを用いて強化された免疫細胞及びそれを含む組成物 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20180004238 | 2018-01-12 | ||
| KR10-2018-0004238 | 2018-01-12 | ||
| JP2020559043A JP7068498B2 (ja) | 2018-01-12 | 2019-01-10 | 二重ｓｈＲＮＡを用いて強化された免疫細胞及びそれを含む組成物 |
| PCT/IB2019/050194 WO2019138354A1 (en) | 2018-01-12 | 2019-01-10 | Enhanced immune cells using dual shrna and composition including the same |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020559043A Division JP7068498B2 (ja) | 2018-01-12 | 2019-01-10 | 二重ｓｈＲＮＡを用いて強化された免疫細胞及びそれを含む組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023200890A Division JP7763824B2 (ja) | 2018-01-12 | 2023-11-28 | 二重ｓｈＲＮＡを用いて強化された免疫細胞及びそれを含む組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022115932A JP2022115932A (ja) | 2022-08-09 |
| JP2022115932A5 true JP2022115932A5 (enExample) | 2023-01-10 |
| JP7394914B2 JP7394914B2 (ja) | 2023-12-08 |
Family
ID=67218229
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020559043A Active JP7068498B2 (ja) | 2018-01-12 | 2019-01-10 | 二重ｓｈＲＮＡを用いて強化された免疫細胞及びそれを含む組成物 |
| JP2022074779A Active JP7394914B2 (ja) | 2018-01-12 | 2022-04-28 | 二重ｓｈＲＮＡを用いて強化された免疫細胞及びそれを含む組成物 |
| JP2023200890A Active JP7763824B2 (ja) | 2018-01-12 | 2023-11-28 | 二重ｓｈＲＮＡを用いて強化された免疫細胞及びそれを含む組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020559043A Active JP7068498B2 (ja) | 2018-01-12 | 2019-01-10 | 二重ｓｈＲＮＡを用いて強化された免疫細胞及びそれを含む組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023200890A Active JP7763824B2 (ja) | 2018-01-12 | 2023-11-28 | 二重ｓｈＲＮＡを用いて強化された免疫細胞及びそれを含む組成物 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US11679129B2 (enExample) |
| EP (2) | EP3737765B2 (enExample) |
| JP (3) | JP7068498B2 (enExample) |
| KR (2) | KR102805915B1 (enExample) |
| CN (1) | CN111801421B (enExample) |
| AU (2) | AU2019206425B2 (enExample) |
| CA (1) | CA3088234A1 (enExample) |
| DK (1) | DK3737765T4 (enExample) |
| ES (2) | ES2908324T5 (enExample) |
| FI (1) | FI3737765T4 (enExample) |
| PL (1) | PL3737765T5 (enExample) |
| PT (1) | PT3737765T (enExample) |
| SG (1) | SG11202006606YA (enExample) |
| WO (1) | WO2019138354A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019079777A1 (en) * | 2017-10-20 | 2019-04-25 | Fred Hutchinson Cancer Research Center | COMPOSITIONS AND METHODS FOR TIGIT AND / OR CD112R TARGETING IMMUNOTHERAPY OR COMPRISING THE OVEREXPRESSION OF CD226 |
| DK3737765T4 (da) | 2018-01-12 | 2025-03-24 | Korea Advanced Inst Sci & Tech | Forstærkede immunceller med dobbelt shrna og sammensætning dermed |
| CN109485732B (zh) * | 2018-12-20 | 2021-09-24 | 四川大学华西医院 | 基因工程修饰的双靶点嵌合抗原受体及其用途 |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| US20220202863A1 (en) * | 2019-05-02 | 2022-06-30 | Celyad | Cells with multiplexed inhibitory rna |
| US20220348928A1 (en) * | 2019-07-17 | 2022-11-03 | Curocell Inc. | Enhanced immune cells using dual shrna and composition including the same |
| KR20220040474A (ko) * | 2019-07-26 | 2022-03-30 | 얀센 바이오테크 인코포레이티드 | 항-hK2 키메라 항원 수용체(CAR) |
| CN120905142A (zh) * | 2019-11-20 | 2025-11-07 | 卡瑟里克斯私人有限公司 | 用于提供具有增强功能的免疫细胞的方法 |
| GB202008688D0 (en) * | 2020-06-09 | 2020-07-22 | Cancer Research Tech Ltd | Chimeric antigen receptor cell |
| WO2022011065A1 (en) * | 2020-07-07 | 2022-01-13 | The Nemours Foundation | Tumor-activated alloreactive and xenoreactive t cells and their use in immunotherapy against cancer |
| CN114075562A (zh) * | 2021-03-10 | 2022-02-22 | 北京肿瘤医院(北京大学肿瘤医院) | Mage-c3抑制剂及其作为制备治疗和/或预防食管鳞状细胞癌药物的用途 |
| CN113416729B (zh) * | 2021-05-18 | 2022-11-22 | 遵义医科大学附属医院 | 一种肝脏靶向调控甲胎蛋白基因的shRNA和cDNA及其应用 |
| CN113403208A (zh) * | 2021-06-15 | 2021-09-17 | 江西科技师范大学 | 高效鉴定米曲霉CRISPR/Cas9突变体的方法 |
| AU2022299474A1 (en) * | 2021-06-23 | 2023-12-21 | Versameb Ag | Compositions and methods for modulating expression of genes |
| PE20241173A1 (es) | 2021-10-14 | 2024-05-28 | Arsenal Biosciences Inc | Celulas inmunitarias que tienen arnhc coexpresados y sistemas de compuerta logica |
| WO2023147776A1 (en) * | 2022-02-07 | 2023-08-10 | Hangzhou Qihan Biotechnology Co., Ltd. | Systems and methods for enhanced immunotherapies |
| EP4282963A1 (en) | 2022-05-23 | 2023-11-29 | Eberhard Karls Universität Tübingen, Medizinische Fakultät | Nucleic acid modified biological cell with expansion-dependent gene expression |
| CN114836428B (zh) * | 2022-06-08 | 2024-03-26 | 华东师范大学 | 一种tigit基因干扰的嵌合抗原受体nk细胞及其应用 |
| WO2023238103A1 (en) * | 2022-06-10 | 2023-12-14 | Curocell Inc. | Car-t therapy for treating cancer |
| CN116983322A (zh) * | 2022-09-15 | 2023-11-03 | 圣诺生物医药技术(苏州)有限公司 | 用于治疗肺癌、胰腺癌、肝癌和结直肠癌的小核酸干扰药物 |
| WO2024186656A1 (en) | 2023-03-03 | 2024-09-12 | Arsenal Biosciences, Inc. | Systems targeting psma and ca9 |
| AU2024256392A1 (en) * | 2023-04-18 | 2025-10-23 | Uniqure Biopharma B.V. | Gene delivery vehicles comprising rna and antibodies |
| CN116515836B (zh) * | 2023-05-09 | 2023-12-01 | 中国人民解放军军事科学院军事医学研究院 | 抑制MerTK表达的shRNA、腺相关病毒及其应用 |
| CN117587014B (zh) * | 2023-11-24 | 2025-01-24 | 上海恩凯细胞技术有限公司 | 多功能基因修饰载体及其制备的多功能基因修饰免疫细胞和它们的应用 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| KR20030032922A (ko) | 2000-02-24 | 2003-04-26 | 싸이트 테라피스 인코포레이티드 | 세포의 동시 자극 및 농축 |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US20070036773A1 (en) * | 2005-08-09 | 2007-02-15 | City Of Hope | Generation and application of universal T cells for B-ALL |
| US20080293142A1 (en) † | 2007-04-19 | 2008-11-27 | The Board Of Regents For Oklahoma State University | Multiple shRNA Expression Vectors and Methods of Construction |
| CA2688514A1 (en) | 2007-04-26 | 2008-11-06 | University Of Iowa Research Foundation | Rna interference suppression of neurodegenerative diseases and methods of use thereof |
| WO2012109667A1 (en) | 2011-02-12 | 2012-08-16 | University Of Iowa Research Foundation | Therapeutic compounds |
| EA201490364A1 (ru) | 2011-07-29 | 2014-08-29 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Костимулирующие рецепторы-переключатели |
| WO2013040557A2 (en) * | 2011-09-16 | 2013-03-21 | The Trustees Of The University Of Pennsylvania | Rna engineered t cells for the treatment of cancer |
| WO2014130657A1 (en) | 2013-02-20 | 2014-08-28 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
| UY35468A (es) * | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| EP3309248B1 (en) | 2013-05-29 | 2021-06-09 | Cellectis | Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system |
| KR102301464B1 (ko) | 2013-06-10 | 2021-09-14 | 다나-파버 캔서 인스티튜트 인크. | 종양 세포에 의한 면역 억제를 감소시키기 위한 방법 및 조성물 |
| EP4026909A1 (en) | 2013-12-19 | 2022-07-13 | Novartis AG | Human mesothelin chimeric antigen receptors and uses thereof |
| EP3593812A3 (en) | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
| SI3888674T1 (sl) * | 2014-04-07 | 2024-08-30 | Novartis Ag | Zdravljenje raka z uporabo antigenskega himernega receptorja proti-CD19 |
| US9523093B2 (en) | 2014-05-20 | 2016-12-20 | University Of Iowa Research Foundation | Huntington's disease therapeutic compounds |
| KR20170075013A (ko) | 2014-10-31 | 2017-06-30 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Cart 세포에서 유전자 발현의 변경 및 그의 용도 |
| US11161907B2 (en) * | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| ES2592578B1 (es) | 2015-05-07 | 2017-12-18 | Dode, S.A. | Mejoras introducidas en la patente de invención "Procedimiento para el tratamiento de granos de maíz destinados a la obtención de palomitas de maíz por medio de aparatos microondas y producto obtenido" |
| HK1258041A1 (zh) * | 2015-09-04 | 2019-11-01 | 纪念斯隆-凯特林癌症中心 | 免疫细胞组合物和使用方法 |
| EP3380620B1 (en) * | 2015-11-23 | 2024-07-03 | Novartis AG | Optimized lentiviral transfer vectors and uses thereof |
| US10366905B2 (en) | 2015-12-11 | 2019-07-30 | Rohm Co., Ltd. | Semiconductor device |
| CN106967681B (zh) * | 2016-01-13 | 2020-06-05 | 北京马力喏生物科技有限公司 | 治疗脑胶质母细胞瘤的治疗组合物 |
| CN106967685B (zh) | 2016-01-13 | 2020-06-02 | 北京马力喏生物科技有限公司 | 共表达抗EGFRvIII嵌合抗原受体和免疫检查点抑制分子的转基因淋巴细胞及其用途 |
| EP3219800A1 (en) | 2016-03-15 | 2017-09-20 | Max-Delbrück-Centrum Für Molekulare Medizin | A transposon-based transfection system for primary cells |
| US11111505B2 (en) * | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| WO2018012895A1 (ko) * | 2016-07-14 | 2018-01-18 | 주식회사 큐로셀 | 면역관문을 극복한 면역세포 및 상기 면역세포를 포함한 약제학적 조성물 |
| CA3036722A1 (en) | 2016-09-14 | 2018-03-22 | Benitec Biopharma Limited | Reagents for producing t-cells with non-functional t-cell receptors (tcrs) compositions comprising same and use thereof |
| WO2018067991A1 (en) * | 2016-10-07 | 2018-04-12 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
| CN107058390A (zh) * | 2017-01-17 | 2017-08-18 | 上海交通大学医学院附属第九人民医院 | 一种慢病毒载体、重组慢病毒质粒、病毒及病毒的应用 |
| EP3585398A4 (en) * | 2017-02-23 | 2020-08-19 | Board of Regents of the University of Nebraska | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER |
| DK3737765T4 (da) | 2018-01-12 | 2025-03-24 | Korea Advanced Inst Sci & Tech | Forstærkede immunceller med dobbelt shrna og sammensætning dermed |
| CN110904045A (zh) | 2018-09-17 | 2020-03-24 | 中国科学院动物研究所 | 经修饰的t细胞、其制备方法及用途 |
| US20220348928A1 (en) | 2019-07-17 | 2022-11-03 | Curocell Inc. | Enhanced immune cells using dual shrna and composition including the same |
-
2019
- 2019-01-10 DK DK19738866.3T patent/DK3737765T4/da active
- 2019-01-10 CA CA3088234A patent/CA3088234A1/en active Pending
- 2019-01-10 ES ES19738866T patent/ES2908324T5/es active Active
- 2019-01-10 EP EP19738866.3A patent/EP3737765B2/en active Active
- 2019-01-10 SG SG11202006606YA patent/SG11202006606YA/en unknown
- 2019-01-10 PL PL19738866.3T patent/PL3737765T5/pl unknown
- 2019-01-10 EP EP21207719.2A patent/EP4006153B1/en active Active
- 2019-01-10 KR KR1020217036928A patent/KR102805915B1/ko active Active
- 2019-01-10 ES ES21207719T patent/ES2990966T3/es active Active
- 2019-01-10 WO PCT/IB2019/050194 patent/WO2019138354A1/en not_active Ceased
- 2019-01-10 JP JP2020559043A patent/JP7068498B2/ja active Active
- 2019-01-10 PT PT197388663T patent/PT3737765T/pt unknown
- 2019-01-10 FI FIEP19738866.3T patent/FI3737765T4/fi active
- 2019-01-10 AU AU2019206425A patent/AU2019206425B2/en active Active
- 2019-01-10 KR KR1020207023221A patent/KR102327512B1/ko active Active
- 2019-01-10 US US16/958,649 patent/US11679129B2/en active Active
- 2019-01-10 CN CN201980016378.1A patent/CN111801421B/zh active Active
-
2021
- 2021-03-18 US US17/205,951 patent/US20210260119A1/en not_active Abandoned
-
2022
- 2022-03-22 US US17/701,535 patent/US12285438B2/en active Active
- 2022-04-28 JP JP2022074779A patent/JP7394914B2/ja active Active
-
2023
- 2023-05-15 US US18/317,797 patent/US20230381236A1/en active Pending
- 2023-11-28 JP JP2023200890A patent/JP7763824B2/ja active Active
-
2025
- 2025-04-22 AU AU2025202789A patent/AU2025202789A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022115932A5 (enExample) | ||
| US11850284B2 (en) | Compositions and methods for delivery of nucleic acids to cells | |
| Zhukovsky et al. | Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection | |
| US10604740B2 (en) | Nucleic acids encoding chimeric antigen receptor proteins which bind epidermal growth factor receptor and T lymphocyte expressing the protein | |
| FI3737765T4 (fi) | Parannettuja immuunisoluja käyttämällä kahta shRNA:ta ja niitä sisältäviä koostumuksia | |
| HRP20240494T1 (hr) | Kimerni antigenski receptori specifični za bcma i njihove upotrebe | |
| RU2015117237A (ru) | Химерные антигенные рецепторы м971 | |
| JP2020513829A5 (enExample) | ||
| CN106967681B (zh) | 治疗脑胶质母细胞瘤的治疗组合物 | |
| RU2016129125A (ru) | Химерные рецепторы антигена против мезотелина человека и их применение | |
| JP2017522879A5 (enExample) | ||
| US11639496B2 (en) | Reducing fratricide of immune cells expressing NKG2D-based receptors | |
| US20240190998A1 (en) | Compositions and methods for delivery of nucleic acids to cells | |
| JP2022509017A (ja) | 抗ｐｔｋ７免疫細胞癌療法 | |
| US20230265214A1 (en) | Compositions and methods for delivery of nucleic acids to cells | |
| KR20210090220A (ko) | 키메라 항원 수용체 기억-유사 (carml) nk 세포 및 이를 만들고, 이용하는 방법 | |
| JPWO2021173995A5 (enExample) | ||
| JPWO2020095107A5 (enExample) | ||
| CN109554349B (zh) | Pd-1基因表达沉默的工程化免疫细胞 | |
| EP4279085A1 (en) | Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease | |
| WO2023169491A1 (zh) | 细胞黏附能力下调的免疫细胞及其医药用途 | |
| EP3974531A1 (en) | Asymmetric sirna inhibiting expression of pd-1 | |
| JP2022532998A (ja) | 選択的イントロンのスプライシングを調節するための方法及び組成物 | |
| JPWO2019226946A5 (enExample) | ||
| WO2024082025A1 (en) | Modified t cells and uses thereof |